Crossmark

Therapeutic potential of a novel semi-synthetic-sulfated-polysaccharide to suppress inflammatory mediators in P. gingivalis LPS stimulated human monocytes/macrophages

Crossref DOI link: https://doi.org/10.1186/s12950-021-00292-6

Published Online: 2021-09-04

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gu, Ying https://orcid.org/0000-0001-6059-7361
Raja, Veena

Lee, Hsi-Ming

Hong, Houlin

Prestwich, Glenn

Ryan, Maria E.
Funding

Funding for this research was provided by:

GlycoMira Therapeutics, Inc.

NIH/NIDCR (1R43DE02216-01)
License Information

Text and Data Mining valid from 2021-09-04

Version of Record valid from 2021-09-04
More Information

Article History

Received: 17 November 2020

Accepted: 6 August 2021

First Online: 4 September 2021

Declarations

:

: Not applicable.

: Not applicable.

: GP is CSO and holds equity in GlycoMira Therapeutics. YG, VR, HL, HH, and MR declare that they have no competing interests.

Document is current

Any future updates will be listed below